ENZN Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 15:30):

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron...

Stats
Dagens volum	701.00
Gjennomsnittsvolum	16 380.00
Markedsverdi	5.57M
EPS	$0 ( 2024-02-09 )
Neste inntjeningsdato	( $0 ) 2024-05-06
Last Dividend	$0.120 ( 2019-09-30 )
Next Dividend	$0 ( N/A )
P/E	-7.50
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-16	Read Randolph C	Buy	84 550	Common Stock
2023-06-14	Read Randolph C	Buy	15 000	Common Stock
2022-06-09	Firestone Jaffrey Adam	Buy	0
2021-08-13	Couchman Jonathan	Sell	57 500	Common Stock, $0.01 par value
2021-08-13	Couchman Jonathan	Sell	50 000	Common Stock, $0.01 par value

INSIDER POWER
100.00
Last 86 transactions
Buy: 34 996 838 \| Sell: 942 903

Enzon Pharmaceuticals, Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Enzon Pharmaceuticals, Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$0.0185

FY	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$0.0185

FY	2022
Omsetning:	$26 000.00
Bruttogevinst:	$26 000.00 (100.00 %)
EPS:	$-0.00250

FY	2021
Omsetning:	$701 000
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.0300

Financial Reports:

No articles found.

Enzon Pharmaceuticals, Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Enzon Pharmaceuticals, Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Information

First Dividend	$2.00	2012-12-06
Last Dividend	$0.120	2019-09-30
Next Dividend	$0	N/A
Payout Date	2019-10-15
Next Payout Date	N/A
# dividends	10	--
Total Paid Out	$5.38	--
Avg. Dividend % Per Year	0.00%	--
Score	0.6	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-06-24)

$0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

0.60

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for PNK

Symbol	Title	Last dividend	Frequency	Yearly Dividend
QNTO	Ex Dividend Knight	2023-07-21	Quarterly	0.00%
JUVF	Ex Dividend Knight	2023-08-16	Quarterly	0.00%
FMBM	Ex Dividend Knight	2023-08-11	Quarterly	0.00%
CPTP	Ex Dividend Knight	2023-08-10	Quarterly	0.00%
WAYN	Ex Dividend Knight	2023-07-18	Quarterly	0.00%
SBYSF	Ex Dividend Junior	2023-09-20	Semi-Annually	0.00%
PKKW	Ex Dividend Junior	2023-09-07	Semi-Annually	0.00%
FULO	Ex Dividend Knight	2023-08-30	Quarterly	0.00%
EMYB	Ex Dividend Knight	2023-06-29	Annually	0.00%
TNCAF	Ex Dividend Junior	2023-08-30	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	0.0288	1.200	9.04	10.00	[0 - 0.3]
returnOnEquityTTM	0.0390	1.500	-0.678	-1.017	[0.1 - 1]
payoutRatioTTM	0.929	-1.000	0.714	-0.714	[0 - 1]
currentRatioTTM	27.62	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	27.43	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	27.43	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.0176	2.00	9.99	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.0176	2.00	9.99	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0	1.000	-3.33	-3.33	[0.2 - 0.8]
operatingProfitMarginTTM	0	1.000	-2.00	-2.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.15

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	4.05	1.000	9.69	0	[1 - 100]
returnOnEquityTTM	0.0390	2.50	-0.436	-1.017	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.0176	2.00	9.99	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.0176	2.00	9.99	10.00	[0 - 30]
payoutRatioTTM	0.929	1.500	0.714	-0.714	[0 - 1]
pegRatioTTM	0.0693	1.500	-2.87	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				2.29

Enzon Pharmaceuticals,

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.

Sanntidsoppdatering for Enzon Pharmaceuticals, [ENZN]

Upcoming Earnings Alert

Enzon Pharmaceuticals, Dividend Information - No Dividend Player

Dividend Commentary

Top 10 dividend Companies for PNK

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)